Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 combined with chemotherapy for advanced solid tumors
CTR20232184Phase 2Active
- Sponsor
- Huabo Biopharm
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sotiburafusp alfa in non-small cell lung cancer (NSCLC), endometrial cancer (EC), Nonhematologic neoplasms, sponsored by Huabo Biopharm. Started Jul 2023; status: active.
02
Drugs
sotiburafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)endometrial cancer (EC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232184.